
Our second session this morning at the 2nd Annual Parkinson’s Disease Prevention Think Tank, co-sponsored by the Parkinson’s Foundation and the University of Florida Norman Fixel Institute for Neurological Diseases, focused on Paraquat and the Policy Landscape. What resonated with me most was the urgent need to bridge the gap between scientific evidence, environmental exposure, and meaningful policy action. Andi Lipstein Fristedt highlighted the growing momentum to restrict environmental toxins linked to Parkinson’s disease and emphasized that progress will require strong research, committed policymakers, and bipartisan champions willing to translate evidence into action. Trevor Archer, PhD, from the National Institute of Environmental Health Sciences (NIEHS), reminded us that prevention requires a broader scientific understanding of environmental exposures, including pesticides such as paraquat, rotenone, and chlorpyrifos, as well as air pollution, metals, and industrial chemicals. NIEHS has an important opportunity to contribute its expertise in exposomics, neurotoxicity, and population studies to the National Plan to End Parkinson’s Disease. Ari Bernstein, MD, MPH, discussed the unique capabilities of the CDC's National Center for Environmental Health and Agency for Toxic Substances and Disease Registry to measure environmental exposures in Americans, monitor vulnerable communities, and leverage experience with disease registries and biobanks, including those developed for ALS. Finally, Jim Jones, discussing the EPA and environmental exposure data, raised perhaps the most provocative issue of the session: the distinction between association and causation. He explained that the EPA has historically required evidence of causality rather than epidemiological association to justify chemical regulation, and that the agency has viewed the relationship between paraquat and Parkinson’s disease as an association without established causality. What resonated with me is that we must confront a fundamental question: How much evidence should society require before taking action to prevent a potentially devastating, irreversible brain disease? Scientific rigor is essential, but waiting for absolute certainty may mean missing opportunities to protect future generations. We need better exposure measurements, stronger science, thoughtful regulation, and policymakers willing to act on the best available evidence. Primary prevention means having the courage to intervene before people develop Parkinson’s disease, rather than waiting until the damage has already been done.





















